Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA approves Oxlumo for primary hyperoxaluria type 1

Nov. 25, 2020

FDA approves Zokinvy for Hutchinson-Gilford progeria syndrome and progeroid laminopathies

Nov. 24, 2020

European researchers discover new NR1I3 agonists

Nov. 24, 2020

Positive topline data from phase II OLE study of Tesomet in hypothalamic obesity

Nov. 24, 2020

Abbisko Therapeutics patents ROR-gammaT agonists

Nov. 23, 2020

First patient dosed in phase I study of SEFA-1024

Nov. 20, 2020

Lumasiran approved in the E.U. for the treatment of PH1

Nov. 20, 2020

Avrobio announces pipeline update and new program in Gaucher disease type 3

Nov. 18, 2020

IND cleared in U.S. for Vivet's phase I/II study of VTX-801 for Wilson's disease

Nov. 18, 2020

Artelo receives clearance for phase I/II trial of ART-27.13 in cancer anorexia

Nov. 17, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...